Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 02'nd Jun 2026
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
10:14pm, Monday, 01'st Jun 2026
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
11:05am, Friday, 29'th May 2026
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
04:05pm, Thursday, 28'th May 2026
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today annou
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
04:05pm, Wednesday, 20'th May 2026
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today annou
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
04:01pm, Wednesday, 13'th May 2026
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:42pm, Friday, 01'st May 2026
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today annou
Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events
09:30am, Tuesday, 28'th Apr 2026
DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup with digital capabilities Speed: Faster payment delivery to holders Seamless Delivery: Full-service sup
Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event
04:05pm, Monday, 20'th Apr 2026
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann
Aberdeen Group plc Grows Stake in Equillium, Inc. $EQ
03:36am, Thursday, 09'th Apr 2026
Aberdeen Group plc grew its holdings in Equillium, Inc. (NASDAQ: EQ) by 523.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 2,366,688 share
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
08:30am, Wednesday, 08'th Apr 2026
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Apr 2026
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
04:05pm, Wednesday, 25'th Mar 2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter
Equillium to Participate in the 38th Annual Roth Conference
08:30am, Wednesday, 18'th Mar 2026
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann
Christine Zedelmayer Sells 120,312 Shares of Equillium (NASDAQ:EQ) Stock
05:00am, Wednesday, 18'th Mar 2026
Equillium, Inc. (NASDAQ: EQ - Get Free Report) COO Christine Zedelmayer sold 120,312 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $2.50, for
